Status:
COMPLETED
Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning
Lead Sponsor:
Oslo University Hospital
Conditions:
Psychosis
Schizophrenia
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
The main objective is to investigate if the brain activation signature of a typical antipsychotic agent is dissociable from a newer drug with a pharmacological profile that differs from both typical a...
Detailed Description
The advent of neuroimaging has opened a new window into the human brain. Here, we propose to investigate if the activation signature of a traditional antipsychotic agent is dissociable from a new drug...
Eligibility Criteria
Inclusion
- Male or Female subject, 18 to 50 years of age
- Capacity to give written informed consent
- Psychiatrically healthy as determined by the MINI interview
Exclusion
- History of head trauma resulting in loss of consciousness \>30 minutes that required medical attention
- Positive screen for pregnancy or current breast feeding
- Serious, unstable medical illness, or any concomitant major medical or neurological illness as determined by history and physical exam
- Used psychotropic medication in the last two years
- Used any drugs/medications/natural product the last two weeks (contraceptives, caffeine and nicotine excluded)
- Metal implants that would preclude an MRI scan
- Clinically relevant abnormalities in the electro-cardiogram (ECG)
- Confirmed clinically significant abnormal laboratory value(s) at screening (lab screen, LFTs, haematology and urine sample will be performed)
- Any history of arterial hypertension or paroxysmal hypertensive states
- Established diagnosis of advanced arteriosclerosis
- Established diagnosis of hyperthyroidism
- Established diagnosis of glaucoma
- History of hypersensitivity to sympathomimetic amines
- History of hypersensitivity to aspirin
- Self-reported feelings of claustrophobia when in narrow environments
- Worked with metal as a grinder, welder etc.
- Lifetime history of substance dependence or abuse (except nicotine and caffeine)
- Systolic blood pressure \> 140 and/or Diastolic blood pressure \>90
- Body weight below 56kg or above 94kg
- History of use of antipsychotic medication
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01161277
Start Date
August 1 2010
End Date
June 1 2011
Last Update
September 12 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital, Ullevål
Oslo, Norway